This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Noven Therapeutics
ClinicalTrials.gov Identifier:
NCT00434213
First received: February 12, 2007
Last updated: March 27, 2017
Last verified: March 2017
February 12, 2007
March 27, 2017
January 2007
August 2007   (Final data collection date for primary outcome measure)
Dermal Reactions [ Time Frame: 7 weeks ]
Dermal reactions were graded on a scale ranging from 0 (no irritation) to 7 (strong reaction) for observed findings of erythema, edema, papules, and vesicles.
To characterize the dermal reactions seen with the use of DAYTRANA. Dermal Assessments will be done once per week during office visit.
Complete list of historical versions of study NCT00434213 on ClinicalTrials.gov Archive Site
Contact Sensitization to Methylphenidate [ Time Frame: 7 weeks ]
Contact sensitization to methylphenidate through skin patch testing.
To identify sensitization through skin patch testing in those subjects whose dermal response scores are observed to be => 6 and also those subjects whose DRS persist at =>4.
Not Provided
Not Provided
 
Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA
A Phase IV, Multi-center, Open-label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD).
This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.
This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks. Subjects will be titrated to an optimum dose of study treatment and assessed for safety and efficacy. Dermal response will be evaluated at each visit by the investigator. Subjects with high dermal response scores or scores that persist at the same application site and have no improvement after up to 4 evaluations (not to exceed a two week period) will be discontinued from the study and referred to a study specific dermatologist for specialized skin sensitivity skin patch testing.
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Attention Deficit Hyperactivity Disorder
Drug: Daytrana
Methylphenidate Transdermal System (MTS)
Other Name: MTS
Experimental: Methylphenidate Transdermal System
To characterize the dermal reactions seen with the use of DAYTRANA
Intervention: Drug: Daytrana
Warshaw EM, Squires L, Li Y, Civil R, Paller AS. Methylphenidate transdermal system: a multisite, open-label study of dermal reactions in pediatric patients diagnosed with ADHD. Prim Care Companion J Clin Psychiatry. 2010;12(6). pii: PCC.10m00996. doi: 10.4088/PCC.10m00996pur.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
309
July 2008
August 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must sign informed consent.
  • Male or female 6-12 years old.
  • Negative pregnancy test.
  • Meet Diagnostic and Statistical Manual of Mental Disorders, 4th edition - Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD.
  • No co-morbid illness that could affect safety, tolerability or interfere with participation.
  • Blood pressure (BP) within the 95th percentile for age, gender, and height.
  • Willing and able to comply with all the requirements defined in protocol.

Exclusion Criteria:

  • Current controlled (requiring a restricted medication) or uncontrolled co-morbid psychiatric diagnosis (except Oppositional Defiant Disorder [ODD]).
  • At risk for suicidal or violent behavior towards self or others.
  • History of a suicide attempt.
  • History of a structural cardiac abnormality or other serious cardiac problems.
  • Non-responder to psychostimulant treatment.
  • Is overweight.
  • Seizures during the last 2 years (exclusive of infantile febrile seizures), a tic disorder, a current diagnosis and/or family history of Tourette's Disorder.
  • Has Conduct Disorder.
  • Known history of alcohol or other substance abuse within the last 6 months.
  • Any abnormal thyroid function.
  • A concurrent chronic or acute illness, disability, or other condition that might confound results of safety assessments.
  • Has had treatment with any known liver altering agents within 30 days prior to Screening.
  • Taking any excluded medication.
  • Previous use of DAYTRANA.
  • Taking other medications that have Central Nervous System (CNS) effects.
  • Female subject is pregnant or lactating.
  • Has any skin disease, or history of any chronic skin disease, skin cancer, skin manifestations of allergic disease, or other dermatologic conditions.
  • Has sensitive-skin syndrome or has sensitivities to the ingredients in soaps, lotions, cosmetics or adhesives.
  • Has clinical signs and symptoms of skin irritation or hyper/hypopigmentation at the potential application sites.
  • A documented allergy, hypersensitivity or intolerance of methylphenidate (MPH) or any components found in DAYTRANA.
Sexes Eligible for Study: All
6 Years to 12 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00434213
SPD485-411
No
Not Provided
Plan to Share IPD: No
Noven Therapeutics
Noven Therapeutics
Not Provided
Principal Investigator: Timothy Wilens, MD Harvard Medical School
Noven Therapeutics
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP